Shira Gabizon Peretz, MD
Research Fellow, Kluger LabAbout
Research
Publications
Featured Publications
Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil/Caelyx): an updated analysis and future perspective
Gabizon A, Gabizon-Peretz S, Modaresahmadi S, La-Beck N. Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil/Caelyx): an updated analysis and future perspective. BMJ Oncology 2025, 4: e000573. PMID: 39885941, PMCID: PMC11751825, DOI: 10.1136/bmjonc-2024-000573.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsPegylated Liposomal DoxorubicinLiposomal doxorubicinClinical approvalFDA approvalCancer therapyRelapsed ovarian cancerMetastatic breast cancerReduction of cardiotoxicityFood and Drug AdministrationImmune modulatory propertiesImpressive reductionMultimodal therapyAdjuvant therapyOvarian cancerBreast cancerEPR effectNano-drugsPharmacological principlesDrug AdministrationTherapyHuman cancersCancerModulatory propertiesComplement systemClinical applicationEmergent Pulmonary Hypertension and Right Ventricular Impairment Following Gemcitabine Therapy for Metastatic Breast Cancer.
Gabizon-Peretz S, Yerushalmi R, Vaturi M, Nardi Agmon I. Emergent Pulmonary Hypertension and Right Ventricular Impairment Following Gemcitabine Therapy for Metastatic Breast Cancer. Israel Medical Association Journal 2025, 27: 319-321. PMID: 40365974.Peer-Reviewed Original ResearchResults of the TARGET-TP Randomized Clinical Trial
Gabizon S, Eizenstein S, Meirson T. Results of the TARGET-TP Randomized Clinical Trial. JAMA Oncology 2024, 10: 988-988. PMID: 38814593, DOI: 10.1001/jamaoncol.2024.0113.Peer-Reviewed Original ResearchBreast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy
Michaelson-Cohen R, Gabizon-Peretz S, Armon S, Srebnik-Moshe N, Mor P, Tomer A, Levy-Lahad E, Paluch-Shimon S. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy. European Journal Of Cancer 2021, 148: 95-102. PMID: 33743487, DOI: 10.1016/j.ejca.2021.02.007.Peer-Reviewed Original ResearchConceptsRisk-Reducing Salpingo-OophorectomyHealthy BRCA1/2 mutation carriersHormone replacement treatmentBRCA1/2 mutation carriersBC riskMutation carriersHRT useBreast cancerShort-term HRT useSalpingo-oophorectomyBreast cancer riskRisk of BCEffect of hormone replacement treatmentHRT groupNatural age of menopauseBRCA1/BRCA2 mutation carriersBC ratesHormone replacement therapyNon-HRT groupBC incidenceBRCA1/BRCA2 carriersAge of menopauseBRCA1/2 carriersBRCA carriersCancer risk
2026
Advances in Cancer Immunotherapy for Solid Tumors
GabizonāPeretz S, Kluger H. Advances in Cancer Immunotherapy for Solid Tumors. Advanced Science 2026, 13: e76020. PMID: 42261754, PMCID: PMC13292180, DOI: 10.1002/advs.76020.Peer-Reviewed Original ResearchConceptsSolid tumorsCancer immunotherapyInhibitors of CTLA-4Tumor-specific immune responsesPD-1/PD-L1 axisManagement of solid tumorsImmune checkpoint blockadeAdoptive cellular therapyImmune-related toxicitiesImmune-modulating strategiesHeterogeneous clinical responseClinical trial design considerationsMechanisms of resistanceCheckpoint blockadeCheckpoint inhibitionCTLA-4Cancer vaccinesImmune checkpointsCytokine therapyTrial design considerationsClinical responseDosing strategiesSystemic toxicityCellular therapyImmune activation